Lacosamide pharmaceutical composition and dosage form thereof

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

Powder for oral suspension containing lamotrigine

This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.

MODIFIED RELEASE OF 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-[5-(4-METHYL-1H-IMIDAZOL-1-YL)-3-(TRIFLOUOROMETHYL)PHENYL] BENZAMIDE SOLUBILIZED USING ORGANIC ACIDS

Soluble pharmaceutical compositions of nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in the form of solid oral dosage forms, including capsules and tablets.

Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren

The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. Aliskiren is shown to slow the dissolution rate of valsartan and the resultant undesirable gelling of valsartan in the presence of aliskiren is overcome by the use of disintegrants. 122-. (canceled)23. A pharmaceutical oral fixed dose solid combination bilayer tablet comprisinga) a first layer comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof and (i) crospovidone, and', '(ii) a polysaccharide chosen from a starch, a starch derivative and a cellulose derivative., 'b) a second layer comprising a therapeutically effective amount of valsartan, or a pharmaceutically acceptable salt thereof, further comprising'}24. The tablet of claim 23 , wherein the starch or starch derivative is a polycarboxyalkyl ether starch claim 23 , a polycarboxymethyl ether starch claim 23 , sodium starch glycolate claim 23 , alginate or a pregelatinized starch.25. The tablet of claim 23 , wherein the polysaccharide comprises glucose or uronic residues.26. The tablet of claim 23 , wherein the cellulose derivative is a polycarboxyalkyl ether cellulose claim 23 , a polycarboxymethyl ether cellulose claim 23 , a low-substituted poly(hydroxylalkyl)ether of cellulose claim 23 , a poly(hydroxypropyl)ether of cellulose claim 23 , croscarmellose sodium or a low-substituted hydroxypropyl cellulose.27. The tablet of claim 23 , wherein the weight ratio of valsartan or the pharmaceutically acceptable salt thereof to component (ii) is from about 15:1 to about 2:1.28. The tablet of claim 27 , wherein the weight ratio of valsartan or the pharmaceutically acceptable salt thereof to component (ii) is from about 8:1 to about 2:1.29. The tablet of claim 28 , wherein the weight ratio of valsartan or the pharmaceutically acceptable salt thereof to component (ii) is from about 6:1 to about 3:1.30. The tablet of claim 23 , wherein the weight ratio of (i) to (ii) is from ...

Lacosamide pharmaceutical composition and dosage form thereof

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 95% or less after 20 minutes, and a dissolution profile of component (b) of 25% or more after 30 minutes, and 45% or more after 60 minutes at pH 4.5, said pharmaceutical oral fixed dose combination being bioequivalent to a free dose combination of Aliskiren and Valsartan.

Pharmaceutical Composition Comprising Aliskiren

The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. It provides compressed bilayer tablets with both a high drug load and suitable physical properties, which can be produced using conventional equipment.

Modified release famciclovir pharmaceutical compositions

A modified release pharmaceutical composition of famciclovir contains at least 60% by weight famciclovir with at least 5% by weight of a release retardant. Particularly useful as a release retardant include polymers, especially a mixture of polyvinyl acetate and polyvinylpyrrolidone. A method of making such pharmaceutical compositions using a extruder and a granulation method is particularly useful.

LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition. 1. A dosage form of lacosamide or a pharmaceutically acceptable salt thereof , comprising an extended release portion , comprising:i. a core comprising lacosamide or a pharmaceutically acceptable salt thereof, andii. an extended release layer enclosing the core, wherein the extended release layer is free from lacosamide or a pharmaceutically acceptable salt thereof and comprises an extended release agent which is pH independent;wherein the core is free from the extended release agent, andwherein the lacosamide or a pharmaceutically acceptable salt thereof in the dosage form has an in-vitro dissolution according to the following:(a) less than about 20% in 1 hour;(b) about 20%-80% in 4 hours; and(c) more than about 80% in 12 hours; wherein the dissolution is determined using a USP type 1 dissolution system (Basket Apparatus) at 100 rpm and a temperature of 37±0.5° C. in 900 ml of pH 6.8 phosphate buffer for 12 hours.2. The dosage form of claim 1 , wherein the core comprises an inert inner core and an outer layer enclosing the inner core claim 1 , and the lacosamide or a pharmaceutically acceptable salt thereof is disposed in the outer layer.3. The dosage form of claim 1 , wherein the lacosamide or a pharmaceutically acceptable salt thereof is uniformly disposed in the core.4. The dosage form of claim 1 , wherein lacosamide or a pharmaceutically acceptable salt thereof in the dosage form has an in-vitro dissolution according to the following:(a) from about 11% to about 18% in 1 hour,(b) from about 20% to about 35% in 2 hours,(c) from about 40% to about 70% in 4 hours,(d) from about 65% to about 95% in 6 hours, and(e) more than about 90% in 12 hours. ...

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

PHARMACEUTICAL COMPOSITION

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

LAMOTRIGINE HYDRATE CRYSTAL FORM, PREPARATION METHOD THEREFOR, AND COMPOSITION CONTAINING SAME

The present invention relates to a crystalline form of a lamotrigine hydrate, a method for preparing the same and a composition comprising the same, and in particular, to a lamotrigine hydrate form A, a method for preparing the lamotrigine hydrate form A and a composition comprising the lamotrigine hydrate form A.

Method for treating bone related diseases and calcium disorders

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

Orally Dosed Pharmaceutical Compositions Comprising a Delivery Agent in Micronized Form

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin. 2. The method of claim 1 , wherein the pharmacologically active polypeptide agent is a calcitonin.3. The method of wherein the calcitonin is salmon calcitonin.4. The method of wherein said inactive excipients are selected from the group consisting of crospovidone and povidone.5. The method of claim 1 , wherein the delivery agent is selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) claim 1 , N-(10-[2-hydroxybenzoly]amino)decanoic acid (SNAD) claim 1 , N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.6. The method according to claim 5 , wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC claim 5 , a disodium salt of SNAD claim 5 , and a disodium salt of SNAG.7. The method of wherein the pharmaceutically active agent further comprises a diluent.8. The method of wherein the diluent is microcrystalline cellulose.9. The method of wherein the pharmaceutically active agent further comprises a lubricant.10. The method of wherein the lubricant is magnesium stearate.11. The method of claim 6 , wherein the delivery agent is the disodium salt of 5-CMAC. This application is a divisional application of U.S. application Ser. No. 12/132,642, filed Jun. 4, 2008, which is a continuation of U.S. application Ser. No. 10/564,259, filed on Aug. 11, 2006, which is a 371 application of PCT/EP2004/007584, filed Jul. 9, 2004, which claims benefit of Provisional Application No. 60/486,495 filed on Jul ...

GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

Powder for oral suspension containing lamotrigine

This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.

Pharmaceutical Composition

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

MELT GRANULATION PROCESS

A process for preparing solid dosage forms that contain a quinoline compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate the quinoline compound with a granulation excipient.

POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGINE

This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases. 1. A powder formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form a stable suspension oral dosage form comprising:lamotrigine or a pharmaceutically acceptable salt thereof; anda suspending agent, wherein the suspending agent is in an amount ranging from about 0.1% to about 10% w/w in the powder formulation, further wherein the suspending agent is effective for maintaining a sedimentation volume ratio of more than about 0.8 for at least 10 hour after the powder formulation is reconstituted into an aqueous suspension.2. The powder formulation of claim 1 , wherein less than about 5% of the lamotrigine is converted to its hydrate form within about 24 hours after the powder formulation is reconstituted into the suspension.3. The powder formulation of claim 1 , wherein less than about 0.5% of the lamotrigine or the pharmaceutically acceptable salt thereof decomposes within about 24 hours after the powder formulation is reconstituted into the suspension.4. The powder formulation of claim 1 , wherein the lamotrigine or the pharmaceutically acceptable salt thereof and the suspending agent have a ratio ranging from about 10:1 to about 10:5 by weight.5. The powder formulation of claim 1 , wherein the lamotrigine or the pharmaceutically acceptable salt thereof and the suspending agent have a ration of about 5:1 by weight.6. The powder formulation of claim 1 , wherein the suspending agent is selected from the group consisting of hydrocolloid gum claim 1 , cellulosic derivative claim 1 , a polysaccharide claim 1 , alginate claim 1 , acrylic acid copolymer claim 1 , polyvmylpyrrohdone claim 1 , aluminiummagnesium silicate claim 1 , and any combination thereof.7. The powder formulation of claim 1 , wherein the suspending agent is hydrocolloid gum.8. The powder formulation of claim 1 ...

Pharmaceutical composition

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

SPRING LOADED DOCKING MECHANISM

An improved docking assembly for faucets having a pull-down sprayhead extendable from a spout. The docking assembly generally comprises a receptacle fitted into the spout which is formed with chamfered interior walls. A spring-loaded flexible collet is contained within the receptacle with a degree of sliding freedom for spring-biased travel along the chamfered interior walls of the receptacle, from a first position that allows generous radial expansion of the collet to a second position in which radial expansion is restricted. A quick-connect fitting attached to the pull-down sprayhead moves the collet into its first position allowing radial expansion of the collet. Removal of the quick-connect fitting moves the collet to its second position which restricts radial expansion, inhibiting said removal. Consequently, the pulldown sprayhead may be docked to the spout with considerably less insertion force than the opposite removal force needed to undock the pulldown sprayhead from the spout. 1. A docking assembly for a pull-out sprayhead extendable from an aperture at a distal end of a faucet spout , comprising:a receptacle fitted within said spout aperture, said receptacle defined as a generally annular member having a longitudinal axis, said receptacle having an interior surface chamfered down to a constricted opening at said spout aperture;a resilient collet contained within said receptacle and adapted for travel along said longitudinal axis from a first position wherein said interior surface allows radial expansion of said collet to a second position wherein said constricted opening inhibits radial expansion of said collet;a spring within said receptacle and engaged to said collet, said spring biasing said collet into said second position; anda fitting attached to said pull-out sprayhead, said fitting comprising an annular member for cooperative insertion into and removal from said receptacle and a distal end for engagement with said collet, whereby insertion of said ...

Sustained Release Pharmaceutical Dosage Form of Entecavir

This document discloses a sustained release dosage form for oral administration of entecavir in a subject. Also disclosed is a method of treating hepatitis virus B infection.

Use of calcitonin in osteoarthritis

The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.

PHARMACEUTICAL COMPOSITION

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly(amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly(amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

PHARMACEUTICAL COMPOSITIONS

A pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), comprising granules that comprise at least therapeutic compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing; processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions for administration thereof; and related uses and methods of treatment. 2. The pharmaceutical composition of claim 1 , wherein the therapeutic compound of formula (I) is 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2 claim 1 ,3-dihydro-imidazo[4 claim 1 ,5-c]quinolin-1-yl)-phenyl]-propionitrile or its monotosylate salt.3. The pharmaceutical composition according to claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is present in an amount ranging from about 30 to about 60% by weight based on the total weight of the composition.4. The pharmaceutical composition according to claim 1 , wherein the at least one non-ionic surfactant that is Vitamin E TPGS is present in an amount ranging from about 15 to about 45% by weight of the composition.5. The pharmaceutical composition according to claim 1 , wherein the at least one dissolution enhancing agent is present in an amount ranging from about 1 to about 15% by weight of the composition.6. The pharmaceutical composition of claim 1 , wherein the at least one dissolution enhancing agent is polyethylene glycol.7. The pharmaceutical composition of claim 6 , wherein the at least one dissolution enhancing agent is PEG3350.8. The pharmaceutical composition according to claim 1 , wherein the composition is formulated in an oral ...

LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

ORALLY DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING A DELIVERY AGENT IN MICRONIZED FORM

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

ORAL FORMULATIONS

Disclosed are pharmaceutical compositions comprising immediate release and sustained release formulations of 5-aminosalicylic acid, or a pharmaceutically acceptable salt or ester thereof, and/or N-acetylcysteine, or a pharmaceutically acceptable salt or ester thereof, for release in the lower gastrointestinal tract.

Spring loaded docking mechanism

An improved docking assembly for faucets having a pull-down sprayhead extendable from a spout. The docking assembly generally comprises a receptacle fitted into the spout which is formed with chamfered interior walls. A spring-loaded flexible collet is contained within the receptacle with a degree of sliding freedom for spring-biased travel along the chamfered interior walls of the receptacle, from a first position that allows generous radial expansion of the collet to a second position in which radial expansion is restricted. A quick-connect fitting attached to the pull-down sprayhead moves the collet into its first position allowing radial expansion of the collet. Removal of the quick-connect fitting moves the collet to its second position which restricts radial expansion, inhibiting said removal. Consequently, the pulldown sprayhead may be docked to the spout with considerably less insertion force than the opposite removal force needed to undock the pulldown sprayhead from the spout.

Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.

LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed 1. A solid dosage form comprising: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer , said polymer coats 7-13% of said core , wherein disintegration of said solid dosage form is delayed by 4-15 minutes.2. The solid dosage form of claim 1 , wherein the polymer is hydroxypropylmethyl cellulose.3. (canceled)4. The solid dosage form of claim 1 , wherein 0-8% of the solid dosage form is dissolved after 5 minutes at pH 2.0.5. The solid dosage form of claim 1 , wherein 45-60% of the solid dosage form is dissolved after 30 minutes at pH 2.0.6. A solid dosage form comprising: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer claim 1 , said polymer coats 7-13% of said core claim 1 , having a fasted state bioavailability equivalent to a hard gelatin capsule claim 1 , wherein its Cand AUC are in the bioequivalent range when compared with capsules comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof.7. The solid dosage form of claim 6 , wherein the polymer is hydroxypropylmethyl cellulose.8. (canceled)9. The solid dosage form of claim 6 , wherein 0-8% by weight of the solid dosage form is dissolved after 5 minutes ...

USE OF CALCITONIN IN OSTEOARTHRITIS

The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.

Use of calcitonin in osteoarthritis

The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.

NOVEL TEBIPENEM PIVOXIL IMMEDIATE AND MODIFIED RELEASE ORAL DOSAGE FORMS

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections. 1. An immediate release solid oral dosage form comprising a dosage form core , wherein the dosage form core comprises:tebipenem pivoxil HBr,wherein the weight to weight ratio of tebipenem pivoxil to the excipients in the core is from 30:60 to 60:30,and excipients including a binder, a lubricant, an optionally a diluent.23-. (canceled)4. The dosage form of claim 1 , wherein the dosage form is an immediate release dosage form and releases more than 85% of the tebipenem pivoxil HBr in 15 minutes when measured by the USP Paddle method at 50 rpm in 900 mL of 50 mM acetate buffer claim 1 , pH 5.0 at 37° C.5. The immediate release dosage form of claim 4 , wherein the excipients additionally comprise a disintegrant.6. The immediate release dosage form of claim 5 , wherein the disintegrant is croscarmellose sodium claim 5 , crospovidone claim 5 , sodium starch glycolate claim 5 , or any combination of any two or more of the foregoing.7. The dosage form of claim 1 , wherein the dosage form is a modified release dosage form and provides an in vitro release of NMT 50% of the tebipenem pivoxil HBr after 30 minutes when measured by the USP Paddle method at 50 rpm in 900 mL of 50 mM acetate buffer claim 1 , pH 5.0 at 37° C.89-. (canceled)10. The modified release dosage form of claim 7 , wherein the excipients additionally comprise a release control agent.11. The modified release dosage form of claim 10 , wherein the release control agent is hydroxypropyl methylcellulose ...

USE OF CALCITONIN IN OSTEOARTHRITIS

The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans. 1. A method of preventing or/and treating osteoarthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a calcitonin in free or salt form.2. A method of inhibiting resorption and/or normalizing turnover of subchondral bone in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a calcitonin in free or salt form.3. The method according to claim 2 , wherein the therapeutically effective amount of a calcitonin is delivered orally.4. The method according to claim 2 , wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin.5. The method according to claim 2 , wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin which is conjugated to a polymer molecule.6. The method according to claim 2 , wherein the therapeutically effective amount of a calcitonin is delivered with an effective dosage of an oral pharmaceutical composition comprising calcitonin claim 2 , at least one pharmaceutically acceptable pH-lowering agent claim 2 , at least one absorption enhancer claim 2 , and an enteric coating.7. The method according to claim 4 , wherein the calcitonin is a salmon calcitonin.8. The method of claim 4 , whereas said pharmaceutical composition comprises a delivery agent selected from the group of 5-CNAC claim 4 , SNAD claim 4 , and SNAC.9. The method according to claim 4 , whereas said pharmaceutical composition comprises a delivery agent selected from the group consisting of a disodium salt of 5-CNAC claim 4 , a disodium salt of SNAD claim 4 , and a disodium salt of SNAC.10. The method according to claim 4 , whereas said ...

Galenical formulations of aliskiren and valsartan

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

Galenical formulations of aliskiren and valsartan

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

Galenical formulations of Aliskiren and Valsartan

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

Oral formulations

Disclosed are pharmaceutical compositions comprising immediate release and sustained release formulations of 5-aminosalicylic acid, or a pharmaceutically acceptable salt or ester thereof, and/or N-acetylcysteine, or a pharmaceutically acceptable salt or ester thereof, for release in the lower gastrointestinal tract.

Pharmaceutical composition

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

Use of calcitonin in osteoarthritis

The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.

Pharmaceutical compositions

The present invention relates to a pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), which comprises granules that comprise at least therapeutic compound of formula (I) (see below), particularly 2-Methyl-2-[4-(3-methyl-2-oxo-8- quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing. The present invention also relates to processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions provide that the pharmaceutical composition may be taken immediately to about thirty minutes after the consumption of food; and related uses and methods of treatment.

Lacosamide pharmaceutical composition and pharmaceutical preparation thereof

The present invention relates to a pharmaceutical composition of lacosamide and a pharmaceutical preparation thereof. The pharmaceutical composition comprises extended release multiparticulates, wherein each of the extended release multiparticulates comprises: (a) a drug-loaded core, comprising lacosamide or a pharmaceutically acceptable salt thereof; and (b) an extended release layer coating the drug-loaded core. The present invention also provides an extended release preparation of lacosamide for once daily oral administration.

Pharmaceutical composition

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

Use of calcitonin in osteoarthritis

Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Soluble pharmaceutical compositions of amorphous nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in th form of solid oral dosage forms, including capsules and tablets.

Galenic Formulations of Organic Compounds

ORGANIC DOSED PHARMACEUTICAL COMPOSITIONS CONTAINING A MICRONIZED SUPPLY AGENT.

Una composición farmacéutica sólida adecuada para el suministro oral de un agente polipeptídico farmacológicamente activo que contiene en donde R 1 , R 2 , R 3 , y R 4 son independientemente hidrógeno, -OH, -NR 6 R 7 , halógeno, alquilo C1-C4, o alcoxi C1-C4; R 5 es un alquileno C2-C16 sustituido o no sustituido, alquenileno C2-C16 sustituido o no sustituido, alquil (arileno) C 1-C 12 sustituido o no sustituido, o aril (alquileno C 1-C 12) sustituido o no sustituido; y R 6 y R 7 son independientemente hidrógeno, oxígeno, o alquilo C1-C4; e hidratos y solvatos de los mismos, en donde dicho agente de suministro está en forma micronizada y tiene un tamaño promedio de partícula de menos de 10 micrones. A solid pharmaceutical composition suitable for oral delivery of a pharmacologically active polypeptide agent containing wherein R 1, R 2, R 3, and R 4 are independently hydrogen, -OH, -NR 6 R 7, halogen, C1-C4 alkyl , or C1-C4 alkoxy; R 5 is a substituted or unsubstituted C2-C16 alkylene, substituted or unsubstituted C2-C16 alkenylene, substituted or unsubstituted C 1 -C 12 alkyl (arylene), or substituted or unsubstituted C 1 -C 12 alkylene ; and R 6 and R 7 are independently hydrogen, oxygen, or C 1 -C 4 alkyl; and hydrates and solvates thereof, wherein said delivery agent is in micronized form and has an average particle size of less than 10 microns.

Galenical formulations of a fixed dose combination of valsartan and aliskiren.

La presente invención se refiere a una combinación farmacéutica oral de dosis fija, la cual comprende: a) una cantidad terapéuticamente efectiva de Alisquireno, o una sal farmacéuticamente aceptable del mismo, b) una cantidad terapéuticamente efectiva de Valsartan, o una sal farmacéuticamente aceptable del mismo, c) un desintegrante, y d) un desintegrante adicional que es un polisacárido.

Use of calcitonin in osteoarthritis

Topical formulations containing mtor inhibitors

A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.

Pharmaceutical composition comprising aliskiren

The present invention relates to a pharmaceutical composition comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a filler; and c) a further specific filler.

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Pharmaceutical compositions

Dosage formulations for organic compounds

La présente invention concerne une combinaison pharmaceutique orale de dose fixe comportant: a) une quantité thérapeutiquement efficace d'aliskirène, ou un sel pharmaceutiquement acceptable de celui-ci, (b) une quantité thérapeutiquement efficace de valsartan, ou un sel pharmaceutiquement acceptable de celui-ci, la combinaison pharmaceutique orale de dose fixe présentant une dissolution in vitro de constituant a) égale ou inférieure à 80% après 10 minutes et égale ou inférieure à 98% après 20 minutes, et un profil de dissolution de constituant b) égal ou supérieur à 25% après 30 minutes, et égal ou supérieur à 40% après 60 minutes à un ph de 4,5. The present invention relates to a fixed dose oral pharmaceutical combination comprising: a) a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, (b) a therapeutically effective amount of valsartan, or a pharmaceutically acceptable salt thereof. here, the fixed dose oral pharmaceutical combination exhibiting an in vitro dissolution of component a) equal to or less than 80% after 10 minutes and equal to or less than 98% after 20 minutes, and a dissolution profile of component b) equal to or greater than 25% after 30 minutes, and equal to or greater than 40% after 60 minutes at a ph of 4.5.

Lacosamide pharmaceutical composition and pharmaceutical preparation thereof

The present invention relates to a pharmaceutical composition of lacosamide and a pharmaceutical preparation thereof. The pharmaceutical composition comprises extended release multiparticulates, wherein each of the extended release multiparticulates comprises: (a) a drug-loaded core, comprising lacosamide or a pharmaceutically acceptable salt thereof; and (b) an extended release layer coating the drug-loaded core. The present invention also provides an extended release preparation of lacosamide for once daily oral administration.

METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONSTA DE UN LUBRICANTE EXTERNO TAL COMO ESTEARATO DE MAGNESIO O CALCIO, FUMARATO DE SODIO,LAURIL-SULFATO DE SODIO, ENTRE OTROS, PARA LA COMPACTACION DE UNA MEZCLA QUE CONTIENE: a) UN PRINCIPIO ACTIVO TAL COMO PROTEINA, POLIPEPTIDO, HORMONA, POLISACARIDO, CARBOHIDRATO, LIPIDO, O UNA COMBINACION DE LOS MISMOS; b) UN AGENTE DE SUMINISTRO, COMO, ACIDO N-(5-CLORO-SALICILOIL)-8-AMINO-CAPRILICO (5-CNAC), ACIDO N-(10-[2-HIDROXI-BENZOIL]-AMINO)-DECANOICO (SNAD), ACIDO N-(8-[2-HIDROXI-BENZOIL]-AMINO)-CAPRILICO (SNAC), O UNA COMBINACION DE LOS MISMOS. DICHA COMPOSICION HACE REFERENCIA A UNA MEJORA EN LAS PROPIEDADES FISICAS DE LA TABLETA TALES COMO, DUREZA, TIEMPO DE DESINTEGRACION Y DISOLUCION IT REFERS TO A PHARMACEUTICAL COMPOSITION THAT CONSISTS OF AN EXTERNAL LUBRICANT SUCH AS MAGNESIUM OR CALCIUM STEARATE, SODIUM FUMARATE, SODIUM LAURYL-SULPHATE, AMONG OTHERS, FOR THE COMPACTION OF A MIXTURE THAT CONTAINS: a) AN ACTIVE PRINCIPLE AS PROTEIN: a) , POLYPEPTIDE, HORMONE, POLYSACCHARIDE, CARBOHYDRATE, LIPID, OR A COMBINATION OF THEM; ( SNAD), N- (8- [2-HYDROXY-BENZOYL] -AMINE) -CAPRYLIC ACID (SNAC), OR A COMBINATION OF THEM. SAID COMPOSITION REFERS TO AN IMPROVEMENT IN THE PHYSICAL PROPERTIES OF THE TABLET SUCH AS HARDNESS, DISINTEGRATION TIME AND DISSOLUTION

Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.

new oral dosage forms of modified and immediate release of tebipenem pivoxil

Formas de dosagem oral de liberação imediata e modificada de tebipenem pivoxil incluindo núcleos de forma de dosagem são fornecidas. O núcleo da forma de dosagem inclui tebipenem pivoxil na forma de base ou sal livre, e excipientes incluindo um ligante, um lubrificante, opcionalmente um diluente, e excipientes adicionais opcionais. A razão de peso para peso de tebipenem pivoxil para os excipientes no núcleo da forma de dosagem é de 30:60 a 60:30. A divulgação inclui métodos de tratamento de infecções bacterianas, incluindo infecções complicadas do trato urinário. Oral dosage forms for immediate and modified release of tebipenem pivoxil including dosage form cores are provided. The core of the dosage form includes tebipenem pivoxil in the form of a base or free salt, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the core of the dosage form is 30:60 to 60:30. The disclosure includes methods of treating bacterial infections, including complicated urinary tract infections.

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

Solid dosage form for immediate release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide; Preparation method.

PHARMACEUTICAL COMPOSITIONS

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN COMPUESTO DE FORMULA (I), DONDE R1 ES NAFTILO, FENILO, ENTRE OTROS; R2 ES O O S; R3 ES ALQUILO C1-C7; R4 ES PIRIDILO, HALOGENO, CIANO, ENTRE OTROS; R5 ES H O HALOGENO; n ES 0 O 1; R6 ES OXIDO; R7 ES H O AMINO, b) UN TENSOACTIVO NO IONICO QUE ES LA VITAMINA E TPGS EN UNA CANTIDAD DE 15% A 80% EN PESO DE LA COMPOSICION, c) UN AGENTE MEJORADOR DE DISOLUCION SELECCIONADO DE POLIETILENGLICOL, POLI-OXIDO DE ETILENO Y COMBINACIONES DE LOS MISMOS. ES COMPUESTO PREFERIDO DE FORMULA (I) EL 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO O SU SAL DE MONOSILATO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS REFERRING TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: a) A COMPOUND OF FORMULA (I), WHERE R1 IS NAPHTHYLUS, PHENYL, AMONG OTHERS; R2 IS O O S; R3 IS C1-C7 ALKYL; R4 IS PYRIDYL, HALOGEN, CYANE, AMONG OTHERS; R5 IS H O HALOGEN; n IS 0 O 1; R6 IS OXIDE; R7 IS HO AMINO, b) A NON-IONIC SURFACTANT WHICH IS VITAMIN E TPGS IN AN AMOUNT OF 15% TO 80% BY WEIGHT OF THE COMPOSITION, c) A DISSOLUTION ENHANCING AGENT SELECTED FROM POLYETHYLENE GLYCOL, POLY-ETHYLENE OXIDE AND COMBINATIONS THEREOF. 2-METHYL-2- [4- (3-METHYL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHYDRO-IMIDAZO- [4,5-c] is the PREFERRED COMPOUND OF FORMULA (I) -QUINOLIN-1-IL) -PHENYL] -PROPIONITRILE OR ITS MONOSILATE SALT. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES

Modified release famciclovir pharmaceutical compositions

A modified release pharmaceutical composition of famciclovir contains at least 60% by weight famciclovir with at least 5% by weight of a release retardant. Particularly useful as a release retardant include polymers, especially a mixture of polyvinyl acetate and polyvinylpyrrolidone. A method of making such pharmaceutical compositions using a extruder and a granulation method is particularly useful.

Modified release famciclovir pharmaceutical compositions

A modified release pharmaceutical composition of famciclovir contains at least 60% by weight famciclovir with at least 5% by weight of a release retardant. Particularly useful as a release retardant include polymers, especially a mixture of polyvinyl acetate and polyvinylpyrrolidone. A method of making such pharmaceutical compositions using a extruder and a granulation method is particularly useful.

Galenic formulations of organic compounds

Pharmazeutische kombination aus aliskiren und valsartan

Topical formulations containing mTOR inhibitors

A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.

Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form

In-mine-shaft seismic monitoring device

Pharmaceutical composition comprising human growth hormon

The invention pertains to a suppository that enables the successful delivery of human growth hormone (hGH), to a subject via administration of said suppository and provides pharmaceutical compositions which are suppositories comprising a human growth hormone as the active ingredient together with the delivery agent 5-CNAC, where the pharmaceutical provides bioavailability, e.g. satisfactory or optimal rectal bioavailability for the human growth hormone active ingredient.

Nuevas formas de dosificacion oral de liberacion inmediata y modificada de tebipenem pivoxil.

Se proporcionan formas de dosificación oral de tebipenem pivoxil de liberación inmediata y modificada que incluyen núcleos de formas de dosificación. El núcleo de la forma de dosificación incluye tebipenem pivoxil en forma de base libre o sal, y excipientes que incluyen un aglutinante, un lubricante, opcionalmente un diluyente, y excipientes adicionales opcionales. La relación peso a peso de tebipenem pivoxil con respecto a los excipientes en el núcleo de la forma de dosificación es de 30:60 a 60:30. La descripción incluye los métodos para tratar infecciones bacterianas, que incluyen infecciones complicadas del tracto urinario.

Nuevas formas de dosificacion oral de liberacion inmediata y modificada de tebipenem pivoxil.

Se proporcionan formas de dosificación oral de tebipenem pivoxil de liberación inmediata y modificada que incluyen núcleos de formas de dosificación. El núcleo de la forma de dosificación incluye tebipenem pivoxil en forma de base libre o sal, y excipientes que incluyen un aglutinante, un lubricante, opcionalmente un diluyente, y excipientes adicionales opcionales. La relación peso a peso de tebipenem pivoxil con respecto a los excipientes en el núcleo de la forma de dosificación es de 30:60 a 60:30. La descripción incluye los métodos para tratar infecciones bacterianas, que incluyen infecciones complicadas del tracto urinario.

Tebipenem pivoxil immediate and modified release oral dosage forms

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Topical formulations containing mtor inhibitors

Device for uniform delivery of inoculant in metal smelting

The present invention relates to the technical field of delivery device, and more particularly to an device for uniform delivery of inoculant in metal smelting. The device includes a guide barrel, a feed pipe is provided on an outer wall of the guide barrel and in communication with the guide barrel, a storage barrel is provided above the guide barrel, a plurality of guide tubes are provided on the bottom of the storage barrel and in communication with the storage barrel, an output of the guide tube is inserted in the guide barrel, a rotary shaft is provided vertically in the guide barrel, a spiral plate is mounted on an outer wall of the rotary shaft, the top of the rotary shaft is extended into the storage barrel, and an opening and closing structure is provided on the top of the rotary shaft. This device enables synchronized delivery and mixture of the inoculant and the liquid metal, thereby effectively preventing premature delivery of the inoculant, which may cause degraded inoculation effect thereof, and improving the uniformity in mixture of the inoculant and the liquid metal to improve the quality of the casting. Meanwhile, automatic control over the amount of delivered inoculant based on the flow rate of the liquid metal can be done conveniently, thereby improving the practicability.

Colorimetric Fan for Measuring Corn Aflatoxin Test and Test Method Thereof

of Descriptions The invention discloses a colorimetric fan for measuring corn aflatoxin test and a test method thereof. The colorimetric fan comprises a plurality of fan blades and rivets for connecting the fan blades, wherein the rivets are spliced with a rotating head; the rotating head is between the rivets and the fan blades on the topmost layer; a shaft sleeve is fixed on the side surface of the rotating head; shaft rods are spliced in the shaft sleeve; first rod bodies are spliced at two ends of the shaft rods; a second rod body is fixedly connected with the first rod body; and a sleeve is spliced with the second rod body. The inner thread of the sleeve is connected with an inner rod, the end of the inner rod extends out of the sleeve and is fixed with a universal shaft, the universal shaft is connected with a needle seat, a thimble is fixed on the needle seat, a plurality of pinholes are formed on the fan blades, and the thimble is matched with the pinholes. The invention ensures that the corn grains do not shake on the fan blades in the measurement process, and the fixed corn grains are convenient for workers to directly visually inspect the color difference between the corn grains and the color comparison fan blades, thereby determining the aflatoxin content and reducing the detection error. Drawings of Descriptions 2- 1 14 12 11 /A Figure 1 6 5 10 13 11 12 3 Figure 2 1/3

Lacosamide pharmaceutical composition and dosage form thereof

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

Libération modifiée de 4-méthyl-3-[ [4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4- méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl] benzamide solubilisé à l'aide d'acides organiques

L'invention concerne des compositions pharmaceutiques solubles de nilotinib ou d'un sel pharmaceutiquement acceptable de celui-ci, utilisant un ou plusieurs acides organiques qui jouent le rôle d'agent solubilisant, augmentant la biodisponibilité du nilotinib et supprimant l'effet nutritif associé à certaines compositions de nilotinib. Les compositions pharmaceutiques se présentent comme formes posologiques solides comprenant les capsules et les comprimés.

Novel tebipenem pivoxil immediate and modified release oral dosage forms

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Novel tebipenem pivoxil immediate and modified release oral dosage forms

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Novel tebipenem pivoxil hbr tablet

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The disclosure includes tebipenem pivoxil HBr tablets comprising at least 55% (w/w) tebipenem pivoxil. The dosage forms may include excipients including a binder, a lubricant, optionally a diluent, and optionally additional excipients. The disclosure also includes the disclosed dosage forms for use in treating bacterial infections including complicated urinary tract infections.

Novel tebipenem pivoxil immediate and modified release oral dosage forms

Novel tebipenem pivoxil immediate and modified release oral dosage forms

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Nuevas formas de dosificacion oral de liberacion inmediata y modificada de tebipenem pivoxil.

Se proporcionan formas de dosificación oral de tebipenem pivoxil de liberación inmediata y modificada que incluye núcleos de formas de dosificación. El núcleo de la forma de dosificación incluye tebipenem pivoxil en forma de base libre o sal, y excipientes que incluyen un aglutinante, un lubricante, opcionalmente un diluyente, y excipientes adicionales opcionales. La relación peso a peso de tebipenem pivoxil con respecto a los excipientes en el núcleo de la forma de dosificación es de 30:60 a 60:30. La descripción incluye los métodos para tratar infecciones bacterianas, que incluyen infecciones complicadas del tracto urinario.

Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Provided is a solid dosage form in the form of a film coated tablet that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide (nilotinib) or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymeric coating over the core, wherein the polymeric coating comprises hydroxypropylmethyl cellulose, and the coating is 7-13% of the dosage form. Also provided is a method for preparing a solid dosage form comprising amorphous 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof comprising the steps of: (i) roller compacting a core comprising 4-Methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) coating said core with at least one polymer.

Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()]

Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida

SE DA A CONOCER UNA FORMA DE DOSIFICACIÓN SÓLIDA DEL NILOTINIB QUE COMPRENDE: (I) UN NÚCLEO QUE COMPRENDE LA 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y EXCIPIENTES; Y (II) CUANDO MENOS UN POLÍMERO, RECUBRIENDO ESTE POLÍMERO AL NÚCLEO, EN DONDE SE DEMORA LA DESINTEGRACIÓN DE LA FORMA DE DOSIFICACIÓN SÓLIDA MENCIONADA.

Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide

L'invention concerne une forme de dosage solide de nilotinib comprenant : (i) un noyau comprenant du 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide ou un sel pharmaceutiquement acceptable de celui-ci et des excipients; et (ii) au moins un polymère, ledit polymère revêtant ledit noyau, la désintégration de ladite forme de dosage solide étant retardée.

Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida

liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida

resumo patente de invenção: "liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida". a presente invenção refere-se à forma de dosagem sólida de nilotinib divulgada, que compreende: (i) um núcleo compreendendo 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida ou a sal farmaceuticamente aceitável da mesma e excipientes; e (ii) pelo menos um polímero, o dito polímero revestindo o dito núcleo, em que a desintegração da dita forma de dosagem sólida é atrasada.

Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Method for preparing pinacolone

A method for preparing pinacolone is provided. Raw materials including isopentane, hydrochloric acid and formaldehyde are reacted in the presence of a catalyst to produce pinacolone. The catalyst is a single lanthanide Lewis acid, a compounded lanthanide Lewis acid or a lanthanide metal oxide soluble in hydrochloric acid. The lanthanide Lewis acid is lanthanum chloride, cerium chloride, praseodymium chloride, neodymium chloride, erbium chloride, holmium chloride, dysprosium chloride or thulium chloride. The method is performed through a continuous two-step reaction. In the first reaction, isopentene and hydrochloric acid are reacted to form an intermediate, which undergoes a second reaction with formaldehyde in the presence of the catalyst to produce pinacolone.